Liminatus Pharma Finalizes Highly Dilutive $3.46M Offering, Significantly Below Prior Target, Amidst Delisting Concerns

summarizeSummary

Liminatus Pharma finalized a highly dilutive $3.46 million public offering, a significant reduction from its initial $9.0 million target, further highlighting its financial distress and Nasdaq delisting risks.

check_boxKey Events · Financing and Capital Events · LIMN

• Finalized Public Offering Terms

  The company is offering 8,270,000 shares of common stock (or pre-funded warrants) and 13,813,000 accompanying warrants to purchase 20,719,500 shares of common stock, at a combined price of $0.29 per unit. This finalizes terms of the offering initiated with the S-1 filing on February 11, 2026.

• Significant Reduction in Capital Raise

  Net proceeds are estimated at $3.46 million, a substantial decrease from the $9.0 million offering initially registered on February 11, 2026, indicating difficulty in securing the full target amount.

• High Dilution for Shareholders

  The offering will increase outstanding common stock by approximately 44.48% (from 31,064,633 to 44,877,633 shares, excluding warrant exercises), resulting in significant dilution for existing shareholders.

• Ongoing Financial Distress and Delisting Risk

  The company continues to operate with "substantial doubt about its ability to continue as a going concern" and faces Nasdaq delisting for failing to maintain a minimum $1 bid price, which this $0.29 offering does not address.

auto_awesomeAnalysis · LIMN · Life Sciences

Liminatus Pharma, a pre-clinical stage biopharmaceutical company, has finalized a public offering of common stock and warrants, aiming to raise approximately $3.46 million in net proceeds. This amount is substantially lower than the $9.0 million offering initially registered in the S-1 filing on February 11, 2026, indicating significant challenges in securing the desired capital. The offering is highly dilutive, increasing outstanding shares by over 44% (excluding warrant exercises), and is priced at $0.29 per share, which is below the Nasdaq minimum bid price of $1.00, for which the company received a delisting notice on January 26, 2026. The company explicitly states "substantial doubt about its ability to continue as a going concern," making this capital raise critical for its short-term operations but insufficient for long-term stability. The reduced proceeds and ongoing financial distress underscore the precarious position of the company.